Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
50K characters. Original on sec.gov ·
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Introduction
This management's discussion and analysis ("MD&A") of financial condition and results of operations is intended to provide investors with an understanding of our recent performance, financial condition and prospects. Dollar amounts are reported in millions, except per share dollar amounts, unless otherwise noted. The following will be discussed and analyzed:
-
Overview of First Quarter 2023 Results
-
Results of Operations and Related Information
-
Liquidity and Capital Resources
-
Information Concerning Forward-Looking Statements
We describe our business outside North America in two groups – Developing and Emerging Markets ("D&E") and Developed Markets. D&E markets comprise Eastern Europe, the Middle East and Africa, Latin America and Asia-Pacific, excluding Australia and South Korea. Developed Markets consist of Western and Central Europe, Australia and South Korea. We have three reportable business segments: Personal Care, Consumer Tissue and K-C Professional. These business segments are described in greater detail in Note 7 to the unaudited interim consolidated financial statements.
On February 24, 2022, we completed our acquisition of a majority and controlling share of Thinx Inc. (“Thinx”), an industry leader in the reusable period and incontinence underwear category, for total consideration of $181 consisting of cash of $53, the fair value of our previously held equity investment of $127, and certain share-based award costs of $1. In the first quarter of 2023, we delivered a redemption notice to the third-party minority owner with respect to a portion of the remaining common securities of Thinx. The redemption will bring our ownership interest in Thinx to 70 percent. We expect the redemption to close in the second quarter of 2023.
On October 24, 2022, we entered into an agreement to sell our Neve tissue brand and related consumer and K-C Professional tissue assets in Brazil for $175, subject to certain working capital and other closing adjustments. The transaction also includes a licensing agreement to allow the acquirer to manufacture and market in Brazil the Kleenex, Scott and Wypall brands to consumers and away-from-home customers for a period of time. Following receipt of antitrust clearance on April 18, 2023, the transaction remains subject to customary conditions and is expected to close in the second quarter of 2023. The assets included in the sale agreement were reclassified to Other current assets as of December 31, 2022.
This section presents a discussion and analysis of our first quarter 2023 net sales, operating profit and other information relevant to an understanding of the results of operations. In addition, we provide commentary regarding organic sales growth, which describes the impact of changes in volume, net selling prices and product mix on net sales. Changes in foreign currency exchange rates and acquisitions also impact the year-over-year change in net sales. Revenue growth management is used to describe our capability that drives sustainable profit growth by maximizing our brands' revenue potential with consumer-centric insights. It focuses on strategic pricing decisions, price pack architecture, managing our product mix, trade promotion activity and trading terms. Our analysis compares the three months ended March 31, 2023 results to the same period in 2022.
Throughout this MD&A, we refer to financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S., or GAAP, and are therefore referred to as non-GAAP financial measures. These measures include adjusted gross and operating profit, adjusted net income, adjusted earnings per share, adjusted other (income) and expense, net and adjusted effective tax rate. We believe these measures provide our investors with additional information about our underlying results and trends, as well as insight into some of the financial measures used to evaluate management.
Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for the comparable GAAP measures, and they should be read only in conjunction with our unaudited interim consolidated financial statements prepared in accordance with GAAP. There are limitations to these non-GAAP financial measures because they are not prepared in accordance with GAAP and may not be comparable to similarly titled measures of other companies due to potential differences in methods of calculation and items being excluded. We compensate for these limitations by using these non-GAAP financial measures as a supplement to the GAAP measures and by providing reconciliations of the non-GAAP and comparable GAAP financial measures.
The non-GAAP financial measures exclude the following item for the relevant time period as indicated in the reconciliations included later in this MD&A:
- Acquisition of controlling interest in Thinx – In the first quarter of 2022, we increased our investment in Thinx. As a result of this transaction, a net benefit was recognized primarily due to the non-recurring, non-cash gain recognized related to the remeasurement of the carrying value of our previously held equity investment to fair value partially
offset by transaction and integration costs. See Item 1, Note 2 to the unaudited interim consolidated financial statements for details.
Overview of First Quarter 2023 Results
-
Net sales of $5.2 billion increased 2 percent compared to the year-ago period, including organic sales growth of 5 percent.
-
Operating profit was $787 in 2023 and $693 in 2022. Net Income Attributable to Kimberly-Clark Corporation was $566 in 2023 compared to $523 in 2022, and diluted earnings per share were $1.67 in 2023 compared to $1.55 in 2022. Results in 2022 include the net benefit of the acquisition of a controlling interest of Thinx.
Results of Operations and Related Information
This section presents a discussion and analysis of our first quarter 2023 net sales, operating profit and other information relevant to an understanding of the results of operations.
Consolidated
| Selected Financial Results | Three Months Ended March 31 | ||||||||||||||||||||||||||||||||||
| 2023 | 2022 | Percent Change | |||||||||||||||||||||||||||||||||
| Net Sales: | |||||||||||||||||||||||||||||||||||
| North America | $ | 2,730 | $ | 2,614 | +4 | % | |||||||||||||||||||||||||||||
| Outside North America | 2,522 | 2,546 | -1 | % | |||||||||||||||||||||||||||||||
| Intergeographic sales | (57) | (65) | -12 | % | |||||||||||||||||||||||||||||||
| Total Net Sales | 5,195 | 5,095 | +2 | % | |||||||||||||||||||||||||||||||
| Operating Profit: | |||||||||||||||||||||||||||||||||||
| North America | 574 | 459 | +25 | % | |||||||||||||||||||||||||||||||
| Outside North America | 312 | 277 | +13 | % | |||||||||||||||||||||||||||||||
| Corporate & Other(a) | (84) | (102) | N.M. | ||||||||||||||||||||||||||||||||
| Other (income) and expense, net(a) | 15 | (59) | N.M. | ||||||||||||||||||||||||||||||||
| Total Operating Profit | 787 | 693 | +14 | % | |||||||||||||||||||||||||||||||
| Share of net income of equity companies | 43 | 23 | +87 | % | |||||||||||||||||||||||||||||||
| Net Income Attributable to Kimberly-Clark Corporation | 566 | 523 | +8 | % | |||||||||||||||||||||||||||||||
| Diluted Earnings per Share | 1.67 | 1.55 | +8 | % |
(a) Corporate & Other and Other (income) and expense, net include income and expense not associated with the business segments, including adjustments as indicated in the Non-GAAP Reconciliations.
N.M. - Not Meaningful
GAAP to Non-GAAP Reconciliations of Selected Financial Results
| Three Months Ended March 31, 2022 | ||||||||||||||||||||||||||
| As Reported | Acquisition of Controlling Interest in Thinx | As Adjusted Non-GAAP | ||||||||||||||||||||||||
| Marketing, research and general expenses | $ | 886 | $ | 21 | $ | 865 | ||||||||||||||||||||
| Other (income) and expense, net | (59) | (85) | 26 | |||||||||||||||||||||||
| Operating Profit | 693 | 64 | 629 | |||||||||||||||||||||||
| Provision for income taxes | (114) | 4 | (118) | |||||||||||||||||||||||
| Effective tax rate | 18.2 | % | — | 21.0 | % | |||||||||||||||||||||
| Net Income Attributable to Kimberly-Clark Corporation | 523 | 68 | 455 | |||||||||||||||||||||||
| Diluted Earnings per Share(a) | 1.55 | 0.20 | 1.35 |
(a) "As Adjusted Non-GAAP" may not equal "As Reported" plus "Adjustments" as a result of rounding.
Analysis of Consolidated Results
| Percent Change in Net Sales Three Months Ended | Volume | Net Price | Mix/Other | Acquisition**(e)** | Currency | Total**(a)** | Organic**(b)** | |||||||||||||||||||||||||||||||||||||||||||||||||
| Consolidated | (5) | 10 | 1 | — | (4) | 2 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||
| North America | (2) | 7 | — | 1 | — | 5 | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||
| D&E Markets | (9) | 11 | 2 | — | (7) | (3) | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Developed Markets | (6) | 15 | 1 | — | (6) | 3 | 10 |
| Percent Change in Operating Profit**(f)** | Volume | Net Price | Input Costs | Cost Savings**(c)** | Currency Translation | Other**(d)** | Total | |||||||||||||||||||||||||||||||||||||
| Three months ended | (10) | 79 | (26) | 16 | (5) | (29) | 25 | |||||||||||||||||||||||||||||||||||||
(a) Total may not equal the sum of volume, net price, mix/other, acquisition and currency due to rounding and excludes intergeographic sales.
(b) Combined impact of changes in volume, net price and mix/other.
(c) Benefits of the FORCE (Focused On Reducing Costs Everywhere) program.
(d) Includes impact of changes in product mix, marketing, research and general expenses, foreign currency transaction effects and other manufacturing costs.
(e) Impact of the acquisition of Thinx Inc.
(f) Percent change calculated using adjusted operating profit for the three months ended March 31, 2022.
Net sales in the first quarter of $5.2 billion increased 2 percent. Organic sales increased 5 percent as changes in net selling prices and product mix increased sales by 10 percent and 1 percent, respectively, driven by ongoing revenue growth management programs, while volume decreased 5 percent. Changes in foreign currency exchange rates decreased sales by approximately 4 percent.
In North America, net sales increased 5 percent, including increases of 2 percent in Personal Care, 5 percent in Consumer Tissue and 12 percent in K-C Professional. Outside North America, net sales decreased 3 percent in D&E Markets and increased 3 percent in Developed Markets.
Operating profit in the first quarter was $787 in 2023 and $693 in 2022. Excluding the net benefit of the acquisition of a controlling interest in Thinx in the first quarter of 2022, adjusted operating profit was $629. Results benefited from higher net selling prices and $105 in FORCE cost savings, partially offset by $160 of higher input costs, driven primarily by fiber and energy costs, higher marketing, research and general expenses, unfavorable currency effects, higher other manufacturing costs and lower volumes.
Interest expense in the first quarter was $73 in 2023 compared to $65 in 2022 primarily due to higher weighted average interest rate on outstanding debt.
The first quarter effective tax rate was 24.5 percent in 2023 and 18.2 percent in 2022. The first quarter adjusted effective tax rate was 21.0 percent in 2022. The rate in 2022 benefited from certain tax planning initiatives.
Our share of net income of equity companies in the first quarter was $43 in 2023 and $23 in 2022. The increase was primarily driven by Kimberly-Clark de Mexico, S.A.B. de C.V. results which benefited from organic sales growth, favorable currency effects, and cost savings partially offset by higher input costs.
Diluted net income per share for the first quarter was $1.67 in 2023 and $1.55 in 2022. First quarter adjusted earnings per share were $1.35 in 2022.
Results by Business Segments
Personal Care
| Three Months Ended March 31 | Three Months Ended March 31 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net Sales | $ | 2,704 | $ | 2,729 | Operating Profit | $ | 487 | $ | 475 |
| Percent Change in Net Sales Three Months Ended | Volume | Net Price | Mix/Other | Acquisition**(e)** | Currency | Total**(a)** | Organic**(b)** | |||||||||||||||||||||||||||||||||||||||||||||||||
| Total Personal Care | (5) | 7 | 1 | 1 | (4) | (1) | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||
| North America | (2) | 4 | (1) | 2 | — | 2 | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||
| D&E Markets | (10) | 11 | 2 | — | (8) | (5) | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Developed Markets | (4) | 7 | 1 | — | (6) | (1) | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Percent Change in Operating Profit | Volume | Net Price | Input Costs | Cost Savings**(c)** | Currency Translation | Other**(d)** | Total | |||||||||||||||||||||||||||||||||||||
| Three months ended | (7) | 40 | (8) | 4 | (5) | (21) | 3 | |||||||||||||||||||||||||||||||||||||
(a) Total may not equal the sum of volume, net price, mix/other, acquisition and currency due to rounding and excludes intergeographic sales.
(b) Combined impact of changes in volume, net price and mix/other.
(c) Benefits of the FORCE program.
(d) Includes impact of changes in product mix, marketing, research and general expenses, foreign currency transaction effects and other manufacturing costs.
(e) Impact of the acquisition of Thinx Inc.
Net sales in the first quarter of $2.7 billion decreased 1 percent, while organic sales increased 3 percent, driven by changes in net selling prices and product mix of 7 percent and 1 percent, respectively, supported by successful revenue growth management and commercial execution, partially offset by decreased volume of 5 percent. Organic sales included an impact from the exit of a private label contract. Changes in foreign currency exchange rates decreased sales by 4 percent.
First quarter operating profit of $487 increased 3 percent. Results benefited from higher net selling prices and cost savings partially offset by higher marketing, research and general expenses, unfavorable currency effects, input cost inflation and lower volumes.
Consumer Tissue
| Three Months Ended March 31 | Three Months Ended March 31 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net Sales | $ | 1,634 | $ | 1,568 | Operating Profit | $ | 240 | $ | 171 | |||||||||||||||||||||||||||||||||||||||||||||||
| Percent Change in Net Sales Three Months Ended | Volume | Net Price | Mix/Other | Currency | Total**(a)** | Organic**(b)** | ||||||||||||||||||||||||||||||||||||||||||||
| Total Consumer Tissue | (5) | 11 | — | (3) | 4 | 7 | ||||||||||||||||||||||||||||||||||||||||||||
| North America | (3) | 7 | 1 | — | 5 | 5 | ||||||||||||||||||||||||||||||||||||||||||||
| D&E Markets | (9) | 13 | 1 | (5) | — | 5 | ||||||||||||||||||||||||||||||||||||||||||||
| Developed Markets | (4) | 17 | — | (7) | 6 | 13 | ||||||||||||||||||||||||||||||||||||||||||||
| Percent Change in Operating Profit | Volume | Net Price | Input Costs | Cost Savings**(c)** | Currency Translation | Other**(d)** | Total | |||||||||||||||||||||||||||||||||||||
| Three months ended | (12) | 101 | (57) | 37 | (2) | (27) | 40 | |||||||||||||||||||||||||||||||||||||
(a) Total may not equal the sum of volume, net price, mix/other and currency due to rounding and excludes intergeographic sales.
(b) Combined impact of changes in volume, net price and mix/other.
(c) Benefits of the FORCE program.
(d) Includes impact of changes in product mix, marketing, research and general expenses, foreign currency transaction effects and other manufacturing costs.
Net sales in the first quarter of $1.6 billion increased 4 percent, including organic sales growth of 7 percent driven by changes in net selling prices that increased sales by 11 percent, partially offset by decreased volume of 5 percent. The segment posted organic growth across all major regions supported by successful revenue growth management and improving service levels. Changes in foreign currency exchange rates decreased sales by 3 percent.
First quarter operating profit of $240 increased 40 percent. Results benefited from higher net selling prices and cost savings, partially offset by input cost inflation, lower volumes and higher other manufacturing costs and marketing, research and general expenses.
K-C Professional
| Three Months Ended March 31 | Three Months Ended March 31 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net Sales | $ | 847 | $ | 780 | Operating Profit | $ | 159 | $ | 90 |
| Percent Change in Net Sales Three Months Ended | Volume | Net Price | Mix/Other | Currency | Total**(a)** | Organic**(b)** | ||||||||||||||||||||||||||||||||||||||||||||
| Total K-C Professional | (6) | 17 | 1 | (3) | 9 | 11 | ||||||||||||||||||||||||||||||||||||||||||||
| North America | (3) | 16 | (1) | (1) | 12 | 12 | ||||||||||||||||||||||||||||||||||||||||||||
| D&E Markets | (6) | 11 | 2 | (6) | 1 | 7 | ||||||||||||||||||||||||||||||||||||||||||||
| Developed Markets | (17) | 26 | 4 | (6) | 7 | 13 | ||||||||||||||||||||||||||||||||||||||||||||
| Percent Change in Operating Profit | Volume | Net Price | Input Costs | Cost Savings**(c)** | Currency Translation | Other**(d)** | Total | |||||||||||||||||||||||||||||||||||||
| Three months ended | (7) | 147 | (31) | 23 | (5) | (50) | 77 | |||||||||||||||||||||||||||||||||||||
(a) Total may not equal the sum of volume, net price, mix/other and currency due to rounding and excludes intergeographic sales.
(b) Combined impact of changes in volume, net price and mix/other.
(c) Benefits of the FORCE program.
(d) Includes impact of changes in product mix, marketing, research and general expenses, foreign currency transaction effects and other manufacturing costs.
First quarter net sales of $847 increased 9 percent, including organic sales growth of 11 percent, driven by changes in net selling prices and product mix of 17 percent and 1 percent, respectively, partially offset by decreased volume of 6 percent. The segment posted organic growth across key categories and regions supported by strong revenue growth management. Changes in foreign currency exchange rates decreased sales by 3 percent.
First quarter operating profit of $159 increased 77 percent. Results benefited from higher net selling prices and cost savings, partially offset by input cost inflation and higher other manufacturing costs.
Liquidity and Capital Resources
Cash Provided by Operations
Cash provided by operations was $613 for the first three months of 2023 compared to $204 in the prior year. The increase was driven by higher operating profit and improvements in working capital.
Investing
During the three months ended March 31, 2023, our capital spending was $201 compared to $253 in the prior year. We anticipate that full year capital spending will be $800 to $900. Acquisition of business, net of cash acquired of $34 in the three months ended March 31, 2022 reflected the acquisition of a controlling interest of Thinx.
Financing
Our short-term debt, which consists of U.S. commercial paper with original maturities up to 90 days and/or other similar short-term debt issued by non-U.S. subsidiaries, was $66 as of March 31, 2023 (included in Debt payable within one year on the consolidated balance sheet). The average month-end balance of short-term debt for the first quarter of 2023 was $315. These short-term borrowings provide supplemental funding to support our operations. The level of short-term debt generally fluctuates depending upon the amount of operating cash flows and the timing of customer receipts and payments for items such as dividends and income taxes.
At March 31, 2023 and December 31, 2022, total debt was $8.5 billion and $8.4 billion, respectively.
In February 2023, we issued $350 aggregate principal amount of 4.50 percent notes due February 16, 2033. Proceeds from the offering were used for general corporate purposes including the repayment of a portion of our commercial paper indebtedness.
Our consolidated subsidiary, Thinx, has issued common securities to its third-party minority owner, who has certain redemption rights to sell those securities to us. In the first quarter of 2023, we delivered a redemption notice with respect to a portion of the remaining common securities held by the third-party minority owner. The redemption value of the securities will consist of cash consideration of approximately $48. We expect the redemption to close in the second quarter of 2023. If the remaining redemption right is exercised, it would require us to pay approximately $185 during a second exercise period of January 1, 2024 through June 30, 2026.
We maintain a $2.0 billion revolving credit facility which expires in June 2026 and a $775 revolving credit facility which expires in June 2023. These facilities, currently unused, support our commercial paper program and would provide liquidity in the event our access to the commercial paper markets is unavailable for any reason.
The United Kingdom’s Financial Conduct Authority, which regulates the London Interbank Offered Rate (“LIBOR”), is in the process of phasing out LIBOR with completion of the phase out expected by June 30, 2023. We have evaluated the potential effect of the elimination of LIBOR and do not expect the effect to be material. Accounting guidance has been issued to ease the transition to alternative reference rates from a financial reporting perspective.
We repurchase shares of Kimberly-Clark common stock from time to time pursuant to publicly announced share repurchase programs. During the first three months of 2023, we repurchased 265 thousand shares of our common stock at a cost of $34 through a broker in the open market. We are targeting full-year 2023 share repurchases of approximately $100 to $150, subject to market conditions.
We believe that our ability to generate cash from operations and our capacity to issue short-term and long-term debt are adequate to fund working capital, capital spending, pension contributions, dividends and other needs for the foreseeable future. Further, we do not expect restrictions or taxes on repatriation of cash held outside of the U.S. to have a material effect on our overall business, liquidity, financial condition or results of operations for the foreseeable future.
Information Concerning Forward-Looking Statements
Certain matters contained in this report concerning the business outlook, including raw material, energy and other input costs, the anticipated cost savings from our FORCE program, cash flow and uses of cash, growth initiatives, innovations, marketing and other spending, net sales, anticipated currency rates and exchange risks, including the impact in Argentina and Turkey, effective tax rate, contingencies and anticipated transactions of Kimberly-Clark, including dividends, share repurchases and pension contributions, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and are based upon management's expectations and beliefs concerning future events impacting Kimberly-Clark. There can be no assurance that these future events will occur as anticipated or that our results will be as estimated. Forward-looking statements speak only as of the date they were made, and we undertake no obligation to publicly update them.
The assumptions used as a basis for the forward-looking statements include many estimates that, among other things, depend on the achievement of future cost savings and projected volume increases. In addition, many factors outside our control, including the war in Ukraine (including the related responses of consumers, customers, and suppliers and sanctions issued by the U.S., the European Union, Russia or other countries), pandemics (including the ongoing COVID-19 outbreak and the related responses of governments, consumers, customers, suppliers and employees), epidemics, fluctuations in foreign currency exchange rates, the prices and availability of our raw materials, supply chain disruptions, disruptions in the capital and credit markets, counterparty defaults (including customers, suppliers and financial institutions with which we do business), failure to realize the expected benefits or synergies from our acquisition and disposition activity (including our pending agreement to sell our Neve tissue brand and associated assets in Brazil), changes in customer preferences, severe weather conditions, government trade or similar regulatory actions, potential competitive pressures on selling prices for our products, energy costs, general economic and political conditions globally and in the markets in which we do business, as well as our ability to maintain key customer relationships, could affect the realization of these estimates.
The factors described under Item 1A, "Risk Factors" in our Form 10-K, or in our other SEC filings, among others, could cause our future results to differ from those expressed in any forward-looking statements made by us or on our behalf. Other factors not presently known to us or that we presently consider immaterial could also affect our business operations and financial results.
Previous: Item 1. Financial Statements · Next: Item 4. Controls and Procedures